RxDoctor Payments Data

Aneeta Gupta, MD

Neurology · Hendersonville, NCNPI 1659370005

Payments from drug & device makers

$12,232in general payments, 2019–2025

Across 599 payments — averaging $20.42 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Livanova USA, Inc.$2K
  • Teva Pharmaceuticals USA, Inc.$1K
  • Novartis$845
  • AstraZeneca$737
  • Biogen$692
  • AbbVie$547
  • plus $6K from 54 others

What the payments were for

  • Speaking & faculty fees$250%
  • Travel & lodging$1,0709%
  • Food & beverage$10,64487%
  • Education$4934%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
Livanova USA, Inc.8$1,619
Teva Pharmaceuticals USA, Inc.93$1,419
Novartis54$845
AstraZeneca(2 entities)24$737
Biogen46$692
AbbVie(2 entities)44$547
Lilly USA, LLC27$523
Eisai Inc.16$411
UCB, Inc.17$361
Pfizer15$284
Johnson & Johnson7$281
MDD US Operations, LLC15$274
SK Life Science, Inc.11$216
Amneal Pharmaceuticals LLC11$213
Argenx US, Inc.10$211
Bristol Myers Squibb10$205
Lundbeck LLC10$194
Amgen13$191
Sanofi9$181
Acadia Pharmaceuticals Inc9$167
Supernus Pharmaceuticals, Inc.12$155
Genentech USA, Inc.8$143
Sunovion Pharmaceuticals Inc.15$142
EMD Serono, Inc.7$142
TG Therapeutics, Inc.6$125
Takeda Pharmaceuticals U.S.A., Inc.5$121
Harmony Biosciences LLC5$119
Adamas Pharmaceuticals, Inc.7$117
E.r. Squibb & Sons, L.L.C.6$111
Sumitomo Pharma America, Inc.6$107
Otsuka America Pharmaceutical, Inc.5$102
Neurocrine Biosciences, Inc.5$86
CSL Behring4$84
Vanda Pharmaceuticals Inc.3$72
Upsher-smith Laboratories LLC3$68
Acorda Therapeutics, Inc4$65
Kyowa Kirin, Inc.3$56
Jazz Pharmaceuticals Inc.3$49
Merz Pharmaceuticals, LLC2$47
Otsuka Pharmaceutical Development & Commercialization, Inc.2$43
Axsome Therapeutics, Inc.2$43
Banner Life Sciences, LLC2$41
Catalyst Pharmaceuticals, Inc.2$41
Merz North America, Inc.2$39
Scilex Pharmaceuticals Inc.2$38
Tanabe Pharma America, Inc.2$38
Bausch Health US, LLC2$36
Grifols USA, LLC2$35
Aquestive Therapeutics, Inc.2$32
Akcea Therapeutics, Inc.2$32
Insightec,inc1$30
Neurelis, Inc.2$27
Assertio Therapeutics, Inc.2$26
ANI Pharmaceuticals, Inc.1$25
Aprecia Pharmaceuticals, LLC1$22
Sanofi-aventis U.S. LLC1$21
GE HealthCare1$21
Avadel CNS Pharmaceuticals, LLC1$20
Biohaven Pharmaceutical Holding Company Ltd.1$20
Avion Pharmaceuticals1$19

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$12,232 in reported general payments places this provider in the 70th percentile of 566 neurology providers in North Carolina.

See all neurology providers in North Carolina

Medicare billing

Part B allowed, 2024
$95,193
Medicare patients
283
Services billed
1,477

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Avonex Pen (4 Pack)Interferon Beta-1a11$102,520
Kesimpta PenOfatumumab11$82,708
Emgality PenGalcanezumab-Gnlm32$22,591
QuliptaAtogepant18$19,629
VimpatLacosamide11$18,828
BriviactBrivaracetam12$17,568
RytaryCarbidopa/Levodopa14$16,522
FycompaPerampanel12$13,779
Rasagiline Mesylate46$9,128
Aimovig AutoinjectorErenumab-Aooe12$9,022
Memantine Hcl389$7,623
Memantine Hcl ErMemantine Hcl52$5,160
Aspirin-Dipyridamole ErAspirin/Dipyridamole13$4,342
Mycophenolate Mofetil43$4,234
Lacosamide27$3,150

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
UCB, Inc.Vimpat, Briviact$361$36,39523 claims
Amneal Pharmaceuticals LLCRytary, Mycophenolate Mofetil$213$20,75657 claims
AbbVieQulipta$547$19,62918 claims
Eisai Inc.Fycompa$411$13,77912 claims
Upsher-smith Laboratories LLCTopiramate$68$1,14359 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 70th percentile of 566 neurology providers in North Carolina.

Other neurology in Hendersonville

See the full list for North Carolina

Where these figures come from

Is this you, or does something look wrong? →